Cancer & Disease Research
How can biopharma innovation be maintained after COVID-19?
Will the speed of biotech innovation seen during the COVID-19 pandemic be maintained going forward, or will the market revert to the status quo? A panel of speakers discussed these questions during a January 7 advance session of the Biotech Showcase, a virtual event to be held January 11-15.  Discuss
Top Operation Warp Speed official shares lessons learned from COVID-19
The global COVID-19 pandemic has placed an urgent burden on governments to serve society, and with the help of the biotechnology and pharmaceutical industries, the job is getting done. That's according to Moncef Slaoui, PhD, chief adviser of the U.S. government's Operation Warp Speed project, who discussed his unique experiences at an advance session of the Biotech Showcase virtual event on January 5.  Discuss
COVID-19 to have long-lasting effect on biotech industry
The COVID-19 pandemic will have a widespread and long-lasting effect on the biotechnology industry, according to speakers at a January 5 presentation held in advance of the Biotech Showcase virtual event taking place January 11-15. Biotech companies have pivoted on a massive scale to pursue infectious disease research -- and not all of them will be successful.  Discuss
Allergic reactions to COVID-19 vaccines shouldn't stop vaccinations
COVID-19 vaccines currently approved for emergency use by the U.S. Food and Drug Administration are safe even among people with food or medication allergies, according to allergists from Massachusetts General Hospital. A review of all relevant information was published in the Journal of Allergy and Clinical Immunology: In Practice on December 31.  Discuss
FDA issues EUA for Moderna COVID-19 vaccine
Just one day after a favorable committee recommendation, the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the messenger RNA (mRNA) COVID-19 vaccine from Moderna. The company's mRNA-1273 vaccine now becomes the second COVID-19 vaccine on the U.S. market, after a vaccine from Pfizer and BioNTech was granted an EUA last week.  Discuss
New discovery could lead to broad-spectrum antivirals
Scientists have identified a key human gene that is required for cells to consume and destroy viruses. The results of the study were published in Nature on December 16 and could point to new treatments to target viral infections, including COVID-19.  Discuss
FDA committee votes favorably for Moderna COVID-19 vaccine EUA
Moderna's messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273, received a favorable recommendation on December 17 from an advisory committee to the U.S. Food and Drug Administration (FDA). The committee's OK means that mRNA-1273 will probably receive an emergency use authorization (EUA) within days.  Discuss
Moderna's vaccine data support high efficacy, safety prior to FDA meeting
Moderna has published information supporting a 94.1% efficacy rate for its messenger RNA (mRNA) COVID-19 vaccine, mRNA-1273. The company made the data available ahead of a December 17 committee meeting at the U.S. Food and Drug Administration (FDA) to review the vaccine candidate.  Discuss
Genes provide new targets for COVID-19 therapies
Genes associated with antiviral immunity and lung inflammation have been tied to severe cases of COVID-19 in a new genome-wide analysis conducted in the U.K. The results, published in Nature on December 11, reveal new therapeutic targets for drug repurposing and development efforts.  Discuss
Global health R&D stalls as resources are redirected to COVID-19
The current coronavirus pandemic has set back progress in research and development (R&D) on neglected diseases and other long-standing global health challenges by disrupting ongoing research and redirecting resources to COVID-19 work, according to a new report released on December 11 by the nonprofit Global Health Technologies Coalition.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter